Glioblastoma Drugs Market Size, Share & Industry Analysis, By Drug (Temozolomide, Bevacizumab, Carmustine, Lomustine, Procarbazine, and Others), By Drug Class (Alkylating Agents, VEGF/Angiogenesis Inhibitors, Nitrosoureas, Platinum Compounds, Topoisomerase Inhibitors, and Others), By Age Group (Pediatric and Adults), By Type (Branded and Generic), By Therapy (Targeted Therapy, Immunotherapy, Chemotherapy, and Others), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Others), and Regional Forecast, 2026-2034

Last Updated: April 30, 2026 | Format: PDF | Report ID: FBI116045

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

Schedule a 30 minutes session to understand our consulting capabilities – SCHEDULE NOW

Table of Content

Introduction
1. Research Scope
2. Market Segmentation
3. Research Methodology
4. Definitions and Assumptions
Executive Summary
Market Dynamics
1. Market Drivers
2. Market Restraints
3. Market Opportunities
4. Market Trends
Key Insights
1. Prevalence of Cancer, By Key Indication, By Key Countries /Regions
2. New Product Launches, By Key Players
3. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
4. Regulatory Scenario, By Key Countries/Regions
Global Glioblastoma Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug
  1. Temozolomide
  2. Bevacizumab
  3. Carmustine
  4. Lomustine
  5. Procarbazine
  6. Irinotecan
  7. Others
2. Market Analysis, Insights and Forecast – By Drug Class
  1. Alkylating Agents
  2. VEGF/Angiogenesis Inhibitors
  3. Nitrosoureas
  4. Platinum Compounds
  5. Topoisomerase Inhibitors
  6. Immune Checkpoint Inhibitors
  7. Others
3. Market Analysis, Insights and Forecast – By Age Group
  1. Pediatric
  2. Adults
4. Market Analysis, Insights and Forecast – By Type
  1. Branded
  2. Generic
5. Market Analysis, Insights and Forecast – By Therapy
  1. Targeted therapy
  2. Immunotherapy
  3. Chemotherapy
  4. Others
6. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
7. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
8. Market Analysis, Insights and Forecast – Region
  1. North America
  2. Europe
  3. Asia Pacific
  4. Latin America
  5. Middle East & Africa
North America Glioblastoma Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug
  1. Temozolomide
  2. Bevacizumab
  3. Carmustine
  4. Lomustine
  5. Procarbazine
  6. Irinotecan
  7. Others
2. Market Analysis, Insights and Forecast – By Drug Class
  1. Alkylating Agents
  2. VEGF/Angiogenesis Inhibitors
  3. Nitrosoureas
  4. Platinum Compounds
  5. Topoisomerase Inhibitors
  6. Immune Checkpoint Inhibitors
  7. Others
3. Market Analysis, Insights and Forecast – By Age Group
  1. Pediatric
  2. Adults
4. Market Analysis, Insights and Forecast – By Type
  1. Branded
  2. Generic
5. Market Analysis, Insights and Forecast – By Therapy
  1. Targeted therapy
  2. Immunotherapy
  3. Chemotherapy
  4. Others
6. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
7. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
8. Market Analysis, Insights and Forecast – By Country
  1. U.S.
  2. Canada
Europe Glioblastoma Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug
  1. Temozolomide
  2. Bevacizumab
  3. Carmustine
  4. Lomustine
  5. Procarbazine
  6. Irinotecan
  7. Others
2. Market Analysis, Insights and Forecast – By Drug Class
  1. Alkylating Agents
  2. VEGF/Angiogenesis Inhibitors
  3. Nitrosoureas
  4. Platinum Compounds
  5. Topoisomerase Inhibitors
  6. Immune Checkpoint Inhibitors
  7. Others
3. Market Analysis, Insights and Forecast – By Age Group
  1. Pediatric
  2. Adults
4. Market Analysis, Insights and Forecast – By Type
  1. Branded
  2. Generic
5. Market Analysis, Insights and Forecast – By Therapy
  1. Targeted therapy
  2. Immunotherapy
  3. Chemotherapy
  4. Others
6. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
7. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
8. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. U.K.
  2. Germany
  3. France
  4. Italy
  5. Spain
  6. Scandinavia
  7. Rest of Europe
Asia Pacific Glioblastoma Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug
  1. Temozolomide
  2. Bevacizumab
  3. Carmustine
  4. Lomustine
  5. Procarbazine
  6. Irinotecan
  7. Others
2. Market Analysis, Insights and Forecast – By Drug Class
  1. Alkylating Agents
  2. VEGF/Angiogenesis Inhibitors
  3. Nitrosoureas
  4. Platinum Compounds
  5. Topoisomerase Inhibitors
  6. Immune Checkpoint Inhibitors
  7. Others
3. Market Analysis, Insights and Forecast – By Age Group
  1. Pediatric
  2. Adults
4. Market Analysis, Insights and Forecast – By Type
  1. Branded
  2. Generic
5. Market Analysis, Insights and Forecast – By Therapy
  1. Targeted therapy
  2. Immunotherapy
  3. Chemotherapy
  4. Others
6. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
7. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
8. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. China
  2. Japan
  3. India
  4. Southeast Asia
  5. Australia
  6. Rest of Asia Pacific
Latin America Glioblastoma Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug
  1. Temozolomide
  2. Bevacizumab
  3. Carmustine
  4. Lomustine
  5. Procarbazine
  6. Irinotecan
  7. Others
2. Market Analysis, Insights and Forecast – By Drug Class
  1. Alkylating Agents
  2. VEGF/Angiogenesis Inhibitors
  3. Nitrosoureas
  4. Platinum Compounds
  5. Topoisomerase Inhibitors
  6. Immune Checkpoint Inhibitors
  7. Others
3. Market Analysis, Insights and Forecast – By Age Group
  1. Pediatric
  2. Adults
4. Market Analysis, Insights and Forecast – By Type
  1. Branded
  2. Generic
5. Market Analysis, Insights and Forecast – By Therapy
  1. Targeted therapy
  2. Immunotherapy
  3. Chemotherapy
  4. Others
6. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
7. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
8. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. Brazil
  2. Mexico
  3. Rest of Latin America
Middle East & Africa Glioblastoma Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug
  1. Temozolomide
  2. Bevacizumab
  3. Carmustine
  4. Lomustine
  5. Procarbazine
  6. Irinotecan
  7. Others
2. Market Analysis, Insights and Forecast – By Drug Class
  1. Alkylating Agents
  2. VEGF/Angiogenesis Inhibitors
  3. Nitrosoureas
  4. Platinum Compounds
  5. Topoisomerase Inhibitors
  6. Immune Checkpoint Inhibitors
  7. Others
3. Market Analysis, Insights and Forecast – By Age Group
  1. Pediatric
  2. Adults
4. Market Analysis, Insights and Forecast – By Type
  1. Branded
  2. Generic
5. Market Analysis, Insights and Forecast – By Therapy
  1. Targeted therapy
  2. Immunotherapy
  3. Chemotherapy
  4. Others
6. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
7. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
8. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. GCC
  2. South Africa
  3. Rest of the Middle East & Africa
Competitive Analysis
1. Global Market Share Analysis (2025)
2. Company Profiles (Overview, Products & Services, SWOT analysis, Recent developments, strategies, financials (based on availability)
  1. Merck & Co., Inc.
  2. Genentech, Inc. (F. Hoffmann-La Roche Ltd)
  3. Teva Pharmaceutical Industries Ltd.
  4. Sun Pharmaceutical Industries Ltd.
  5. Accord Healthcare
  6. Camber Pharmaceuticals, Inc.
  7. Fresenius Kabi AG
  8. Zydus Lifesciences Ltd.
  9. Amneal Pharmaceuticals, Inc.

Introduction
1. Research Scope
2. Market Segmentation
3. Research Methodology
4. Definitions and Assumptions
Executive Summary
Market Dynamics
1. Market Drivers
2. Market Restraints
3. Market Opportunities
4. Market Trends
Key Insights
1. Prevalence of Cancer, By Key Indication, By Key Countries /Regions
2. New Product Launches, By Key Players
3. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
4. Regulatory Scenario, By Key Countries/Regions
Global Glioblastoma Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug
  1. Temozolomide
  2. Bevacizumab
  3. Carmustine
  4. Lomustine
  5. Procarbazine
  6. Irinotecan
  7. Others
2. Market Analysis, Insights and Forecast – By Drug Class
  1. Alkylating Agents
  2. VEGF/Angiogenesis Inhibitors
  3. Nitrosoureas
  4. Platinum Compounds
  5. Topoisomerase Inhibitors
  6. Immune Checkpoint Inhibitors
  7. Others
3. Market Analysis, Insights and Forecast – By Age Group
  1. Pediatric
  2. Adults
4. Market Analysis, Insights and Forecast – By Type
  1. Branded
  2. Generic
5. Market Analysis, Insights and Forecast – By Therapy
  1. Targeted therapy
  2. Immunotherapy
  3. Chemotherapy
  4. Others
6. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
7. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
8. Market Analysis, Insights and Forecast – Region
  1. North America
  2. Europe
  3. Asia Pacific
  4. Latin America
  5. Middle East & Africa
North America Glioblastoma Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug
  1. Temozolomide
  2. Bevacizumab
  3. Carmustine
  4. Lomustine
  5. Procarbazine
  6. Irinotecan
  7. Others
2. Market Analysis, Insights and Forecast – By Drug Class
  1. Alkylating Agents
  2. VEGF/Angiogenesis Inhibitors
  3. Nitrosoureas
  4. Platinum Compounds
  5. Topoisomerase Inhibitors
  6. Immune Checkpoint Inhibitors
  7. Others
3. Market Analysis, Insights and Forecast – By Age Group
  1. Pediatric
  2. Adults
4. Market Analysis, Insights and Forecast – By Type
  1. Branded
  2. Generic
5. Market Analysis, Insights and Forecast – By Therapy
  1. Targeted therapy
  2. Immunotherapy
  3. Chemotherapy
  4. Others
6. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
7. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
8. Market Analysis, Insights and Forecast – By Country
  1. U.S.
  2. Canada
Europe Glioblastoma Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug
  1. Temozolomide
  2. Bevacizumab
  3. Carmustine
  4. Lomustine
  5. Procarbazine
  6. Irinotecan
  7. Others
2. Market Analysis, Insights and Forecast – By Drug Class
  1. Alkylating Agents
  2. VEGF/Angiogenesis Inhibitors
  3. Nitrosoureas
  4. Platinum Compounds
  5. Topoisomerase Inhibitors
  6. Immune Checkpoint Inhibitors
  7. Others
3. Market Analysis, Insights and Forecast – By Age Group
  1. Pediatric
  2. Adults
4. Market Analysis, Insights and Forecast – By Type
  1. Branded
  2. Generic
5. Market Analysis, Insights and Forecast – By Therapy
  1. Targeted therapy
  2. Immunotherapy
  3. Chemotherapy
  4. Others
6. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
7. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
8. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. U.K.
  2. Germany
  3. France
  4. Italy
  5. Spain
  6. Scandinavia
  7. Rest of Europe
Asia Pacific Glioblastoma Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug
  1. Temozolomide
  2. Bevacizumab
  3. Carmustine
  4. Lomustine
  5. Procarbazine
  6. Irinotecan
  7. Others
2. Market Analysis, Insights and Forecast – By Drug Class
  1. Alkylating Agents
  2. VEGF/Angiogenesis Inhibitors
  3. Nitrosoureas
  4. Platinum Compounds
  5. Topoisomerase Inhibitors
  6. Immune Checkpoint Inhibitors
  7. Others
3. Market Analysis, Insights and Forecast – By Age Group
  1. Pediatric
  2. Adults
4. Market Analysis, Insights and Forecast – By Type
  1. Branded
  2. Generic
5. Market Analysis, Insights and Forecast – By Therapy
  1. Targeted therapy
  2. Immunotherapy
  3. Chemotherapy
  4. Others
6. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
7. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
8. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. China
  2. Japan
  3. India
  4. Southeast Asia
  5. Australia
  6. Rest of Asia Pacific
Latin America Glioblastoma Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug
  1. Temozolomide
  2. Bevacizumab
  3. Carmustine
  4. Lomustine
  5. Procarbazine
  6. Irinotecan
  7. Others
2. Market Analysis, Insights and Forecast – By Drug Class
  1. Alkylating Agents
  2. VEGF/Angiogenesis Inhibitors
  3. Nitrosoureas
  4. Platinum Compounds
  5. Topoisomerase Inhibitors
  6. Immune Checkpoint Inhibitors
  7. Others
3. Market Analysis, Insights and Forecast – By Age Group
  1. Pediatric
  2. Adults
4. Market Analysis, Insights and Forecast – By Type
  1. Branded
  2. Generic
5. Market Analysis, Insights and Forecast – By Therapy
  1. Targeted therapy
  2. Immunotherapy
  3. Chemotherapy
  4. Others
6. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
7. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
8. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. Brazil
  2. Mexico
  3. Rest of Latin America
Middle East & Africa Glioblastoma Drugs Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Drug
  1. Temozolomide
  2. Bevacizumab
  3. Carmustine
  4. Lomustine
  5. Procarbazine
  6. Irinotecan
  7. Others
2. Market Analysis, Insights and Forecast – By Drug Class
  1. Alkylating Agents
  2. VEGF/Angiogenesis Inhibitors
  3. Nitrosoureas
  4. Platinum Compounds
  5. Topoisomerase Inhibitors
  6. Immune Checkpoint Inhibitors
  7. Others
3. Market Analysis, Insights and Forecast – By Age Group
  1. Pediatric
  2. Adults
4. Market Analysis, Insights and Forecast – By Type
  1. Branded
  2. Generic
5. Market Analysis, Insights and Forecast – By Therapy
  1. Targeted therapy
  2. Immunotherapy
  3. Chemotherapy
  4. Others
6. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Parenteral
7. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Drug Stores & Retail Pharmacies
  3. Online Pharmacies
8. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. GCC
  2. South Africa
  3. Rest of the Middle East & Africa
Competitive Analysis
1. Global Market Share Analysis (2025)
2. Company Profiles (Overview, Products & Services, SWOT analysis, Recent developments, strategies, financials (based on availability)
  1. Merck & Co., Inc.
  2. Genentech, Inc. (F. Hoffmann-La Roche Ltd)
  3. Teva Pharmaceutical Industries Ltd.
  4. Sun Pharmaceutical Industries Ltd.
  5. Accord Healthcare
  6. Camber Pharmaceuticals, Inc.
  7. Fresenius Kabi AG
  8. Zydus Lifesciences Ltd.
  9. Amneal Pharmaceuticals, Inc.

Read Less

List of Figures

Figure 1: Global Glioblastoma Drugs Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034

Figure 2: Global Glioblastoma Drugs Market Value Share (%), By Drug, 2025 & 2034

Figure 3: Global Glioblastoma Drugs Market Value Share (%), By Drug Class, 2025 & 2034

Figure 4: Global Glioblastoma Drugs Market Value Share (%), by Age Group, 2025 & 2034

Figure 5: Global Glioblastoma Drugs Market Value Share (%), by Type, 2025 & 2034

Figure 6: Global Glioblastoma Drugs Market Value Share (%), by Route of Administration, 2025 & 2034

Figure 7: Global Glioblastoma Drugs Market Value Share (%), by Therapy, 2025 & 2034

Figure 8: Global Glioblastoma Drugs Market Value Share (%), by Distribution Channel, 2025 & 2034

Figure 9: Global Glioblastoma Drugs Market Value Share (%), by Region, 2025 & 2034

Figure 10: North America Glioblastoma Drugs Market Value (USD billion), by Drug, 2025 & 2034

Figure 11: North America Glioblastoma Drugs Market Value Share (%), By Drug, 2025

Figure 12: North America Glioblastoma Drugs Market Value (USD billion), By Drug Class, 2025 & 2034

Figure 13: North America Glioblastoma Drugs Market Value Share (%), By Drug Class, 2025

Figure 14: North America Glioblastoma Drugs Market Value (USD billion), by Age Group 2025 & 2034

Figure 15: North America Glioblastoma Drugs Market Value Share (%), by Age Group 2025

Figure 16: North America Glioblastoma Drugs Market Value (USD billion), by Type, 2025 & 2034

Figure 17: North America Glioblastoma Drugs Market Value Share (%), by Type, 2025

Figure 18: North America Glioblastoma Drugs Market Value (USD billion), by Therapy, 2025 & 2034

Figure 19: North America Glioblastoma Drugs Market Value Share (%), by Therapy, 2025

Figure 20: North America Glioblastoma Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034

Figure 21: North America Glioblastoma Drugs Market Value Share (%), by Route of Administration, 2025

Figure 22: North America Glioblastoma Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034

Figure 23: North America Glioblastoma Drugs Market Value Share (%), by Distribution Channel, 2025

Figure 24: North America Glioblastoma Drugs Market Value (USD billion), by Country, 2025 & 2034

Figure 25: North America Glioblastoma Drugs Market Value Share (%), by Country, 2025

Figure 26: Europe Glioblastoma Drugs Market Value (USD billion), by Drug, 2025 & 2034

Figure 27: Europe Glioblastoma Drugs Market Value Share (%), By Drug, 2025

Figure 28: Europe Glioblastoma Drugs Market Value (USD billion), By Drug Class, 2025 & 2034

Figure 29: Europe Glioblastoma Drugs Market Value Share (%), By Drug Class, 2025

Figure 30: Europe Glioblastoma Drugs Market Value (USD billion), by Age Group 2025 & 2034

Figure 31: Europe Glioblastoma Drugs Market Value Share (%), by Age Group 2025

Figure 32: Europe Glioblastoma Drugs Market Value (USD billion), by Type, 2025 & 2034

Figure 33: Europe Glioblastoma Drugs Market Value Share (%), by Type, 2025

Figure 34: Europe Glioblastoma Drugs Market Value (USD billion), by Therapy, 2025 & 2034

Figure 35: Europe Glioblastoma Drugs Market Value Share (%), by Therapy, 2025

Figure 36: Europe Glioblastoma Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034

Figure 37: Europe Glioblastoma Drugs Market Value Share (%), by Route of Administration, 2025

Figure 38: Europe Glioblastoma Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034

Figure 39: Europe Glioblastoma Drugs Market Value Share (%), by Distribution Channel, 2025

Figure 40: Europe Glioblastoma Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034

Figure 41: Europe Glioblastoma Drugs Market Value Share (%), by Country/ Sub-region, 2025

Figure 42: Asia Pacific Glioblastoma Drugs Market Value (USD billion), by Drug, 2025 & 2034

Figure 43: Asia Pacific Glioblastoma Drugs Market Value Share (%), By Drug, 2025

Figure 44: Asia Pacific Glioblastoma Drugs Market Value (USD billion), By Drug Class, 2025 & 2034

Figure 45: Asia Pacific Glioblastoma Drugs Market Value Share (%), By Drug Class, 2025

Figure 46: Asia Pacific Glioblastoma Drugs Market Value (USD billion), by Age Group 2025 & 2034

Figure 47: Asia Pacific Glioblastoma Drugs Market Value Share (%), by Age Group 2025

Figure 48: Asia Pacific Glioblastoma Drugs Market Value (USD billion), by Type, 2025 & 2034

Figure 49: Asia Pacific Glioblastoma Drugs Market Value Share (%), by Type, 2025

Figure 50: Asia Pacific Glioblastoma Drugs Market Value (USD billion), by Therapy, 2025 & 2034

Figure 51: Asia Pacific Glioblastoma Drugs Market Value Share (%), by Therapy, 2025

Figure 52: Asia Pacific Glioblastoma Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034

Figure 53: Asia Pacific Glioblastoma Drugs Market Value Share (%), by Route of Administration, 2025

Figure 54: Asia Pacific Glioblastoma Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034

Figure 55: Asia Pacific Glioblastoma Drugs Market Value Share (%), by Distribution Channel, 2025

Figure 56: Asia Pacific Glioblastoma Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034

Figure 57: Asia Pacific Glioblastoma Drugs Market Value Share (%), by Country/ Sub-region, 2025

Figure 58: Latin America Glioblastoma Drugs Market Value (USD billion), by Drug, 2025 & 2034

Figure 59: Latin America Glioblastoma Drugs Market Value Share (%), By Drug, 2025

Figure 60: Latin America Glioblastoma Drugs Market Value (USD billion), By Drug Class, 2025 & 2034

Figure 61: Latin America Glioblastoma Drugs Market Value Share (%), By Drug Class, 2025

Figure 62: Latin America Glioblastoma Drugs Market Value (USD billion), by Age Group 2025 & 2034

Figure 63: Latin America Glioblastoma Drugs Market Value Share (%), by Age Group 2025

Figure 64: Latin America Glioblastoma Drugs Market Value (USD billion), by Type, 2025 & 2034

Figure 65: Latin America Glioblastoma Drugs Market Value Share (%), by Type, 2025

Figure 66: Latin America Glioblastoma Drugs Market Value (USD billion), by Therapy, 2025 & 2034

Figure 67: Latin America Glioblastoma Drugs Market Value Share (%), by Therapy, 2025

Figure 68: Latin America Glioblastoma Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034

Figure 69: Latin America Glioblastoma Drugs Market Value Share (%), by Route of Administration, 2025

Figure 70: Latin America Glioblastoma Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034

Figure 71: Latin America Glioblastoma Drugs Market Value Share (%), by Distribution Channel, 2025

Figure 72: Latin America Glioblastoma Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034

Figure 73: Latin America Glioblastoma Drugs Market Value Share (%), by Country/ Sub-region, 2025

Figure 74: Middle East & Africa Glioblastoma Drugs Market Value (USD billion), by Drug, 2025 & 2034

Figure 75: Middle East & Africa Glioblastoma Drugs Market Value Share (%), By Drug, 2025

Figure 76: Middle East & Africa Glioblastoma Drugs Market Value (USD billion), By Drug Class, 2025 & 2034

Figure 77: Middle East & Africa Glioblastoma Drugs Market Value Share (%), By Drug Class, 2025

Figure 78: Middle East & Africa Glioblastoma Drugs Market Value (USD billion), by Age Group 2025 & 2034

Figure 79: Middle East & Africa Glioblastoma Drugs Market Value Share (%), by Age Group 2025

Figure 80: Middle East & Africa Glioblastoma Drugs Market Value (USD billion), by Type, 2025 & 2034

Figure 81: Middle East & Africa Glioblastoma Drugs Market Value Share (%), by Type, 2025

Figure 82: Middle East & Africa Glioblastoma Drugs Market Value (USD billion), by Therapy, 2025 & 2034

Figure 83: Middle East & Africa Glioblastoma Drugs Market Value Share (%), by Therapy, 2025

Figure 84: Middle East & Africa Glioblastoma Drugs Market Value (USD billion), by Route of Administration, 2025 & 2034

Figure 85: Middle East & Africa Glioblastoma Drugs Market Value Share (%), by Route of Administration, 2025

Figure 86: Middle East & Africa Glioblastoma Drugs Market Value (USD billion), by Distribution Channel, 2025 & 2034

Figure 87: Middle East & Africa Glioblastoma Drugs Market Value Share (%), by Distribution Channel, 2025

Figure 88: Middle East & Africa Glioblastoma Drugs Market Value (USD billion), by Country/ Sub-region, 2025 & 2034

Figure 89: Middle East & Africa Glioblastoma Drugs Market Value Share (%), by Country/ Sub-region, 2025

Figure 90: Global Glioblastoma Drugs Market Share (%), by Company, 2025

List of Tables

Table 1: Global Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Drug, 2021–2034

Table 2: Global Glioblastoma Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2021–2034

Table 3: Global Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Age Group 2021–2034

Table 4: Global Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Type, 2021–2034

Table 5: Global Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Therapy, 2021–2034

Table 6: Global Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2021–2034

Table 7: Global Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021–2034

Table 8: Global Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Region, 2021-2034

Table 9: North America Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Drug, 2021–2034

Table 10: North America Glioblastoma Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2021–2034

Table 11: North America Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Age Group 2021–2034

Table 12: North America Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Type, 2021–2034

Table 13: North America Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Therapy, 2021–2034

Table 14: North America Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2021–2034

Table 15: North America Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021–2034

Table 16: North America Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Country, 2021-2034

Table 17: Europe Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Drug, 2021–2034

Table 18: Europe Glioblastoma Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2021–2034

Table 19: Europe Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Age Group 2021–2034

Table 20: Europe Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Type, 2021–2034

Table 21: Europe Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Therapy, 2021–2034

Table 22: Europe Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2021–2034

Table 23: Europe Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021–2034

Table 24: Europe Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

Table 25: Asia Pacific Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Drug, 2021–2034

Table 26: Asia Pacific Glioblastoma Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2021–2034

Table 27: Asia Pacific Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Age Group 2021–2034

Table 28: Asia Pacific Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Type, 2021–2034

Table 29: Asia Pacific Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Therapy, 2021–2034

Table 30: Asia Pacific Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2021–2034

Table 31: Asia Pacific Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021–2034

Table 32: Asia Pacific Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

Table 33: Latin America Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Drug, 2021–2034

Table 34: Latin America Glioblastoma Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2021–2034

Table 35: Latin America Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Age Group 2021–2034

Table 36: Latin America Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Type, 2021–2034

Table 37: Latin America Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Therapy, 2021–2034

Table 38: Latin America Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2021–2034

Table 39: Latin America Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021–2034

Table 40: Latin America Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

Table 41: Middle East & Africa Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Drug, 2021–2034

Table 42: Middle East & Africa Glioblastoma Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2021–2034

Table 43: Middle East & Africa Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Age Group 2021–2034

Table 44: Middle East & Africa Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Type, 2021–2034

Table 45: Middle East & Africa Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Therapy, 2021–2034

Table 46: Middle East & Africa Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2021–2034

Table 47: Middle East & Africa Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Distribution Channel, 2021–2034

Table 48: Middle East & Africa Glioblastoma Drugs Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

STUDY PERIOD: 2021-2034
BASE YEAR: 2025
HISTORICAL DATA: 2021-2024
NO OF PAGES: 190

Buy Now

Download Free Sample

Security Code

Get 20% Free Customization

Expand Regional and Country Coverage, Segments Analysis, Company Profiles, Competitive Benchmarking, and End-user Insights.

Growth Advisory Services

Clients

Related Reports

Get In Touch With Us

US +1 833 909 2966 ( Toll Free )

UK +44 808 502 0280 ( Toll Free )

(APAC) +91 744 740 1245
sales@fortunebusinessinsights.com